Open Label Study for the Functional Characterization of Drug Metabolism and Transport

PHASE1CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Genotype-related Drug Metabolism
Interventions
DRUG

Codeine

A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

DRUG

Midazolam

A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

DRUG

pravastatin

A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

DRUG

Talinolol

A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

DRUG

torsemide

A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).

Trial Locations (2)

70376

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart

72076

Abteilung Klinische Pharmakologie, Tübingen

All Listed Sponsors
lead

Matthias Schwab

OTHER

NCT01788254 - Open Label Study for the Functional Characterization of Drug Metabolism and Transport | Biotech Hunter | Biotech Hunter